ghk-cu copper peptide hair growth evidence clinical trial Research GHK-Cu for Hair Growth: What

E-Posters - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION 06.00 - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION - 06.02 - GENETICS, OMICS AND BIOMARKERS P2586 - ESOC25-1678 ATYPICAL PRESENTATIONS IN CADASIL: INTRACRANIAL HAEMORRHAGE AS INDEX PRESENTATION Monturayo Wadzani 1 , Mark Maskery 1 , Amna Sajjad 1 , Mohamed Attia 1 , Ayesha Muneer 1 , Kirsty Ward 1 , Syeda Ismail 1 , Simina Cozma 1 , Dwaipayan Sen 1,2 1 Greater Manchester Comprehensive Stroke Centre, Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford Royal Hospital, Manchester, United Kingdom, 2 Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom Background and Aims: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) caused by pathogenic mutations in NOTCH 3 gene is a leading cause of monogenic cerebral small vessel disease resulting in ischaemic strokes and vascular dementia

Therapeutic-grade prescription compounded GHK-Cu is not available through retail channels, because it requires a licensed provider and a compounding pharmacy

These risks are exactly why an intramuscular injection is safer given by a trained clinician than self-administered at home

It upregulates angiogenic signaling in endothelial models through increased VEGF and VEGFR2 activity

B., Fundaun, J